SEARCH

SEARCH BY CITATION

References

  • 1
    Cook T, Sheridan WP. Development of GnRH antagonists for prostate cancer: new approaches to treatment. Oncologist 2000; 5: 1628.
  • 2
    Nelson WG, De Marzo AM, Isaacs WB. Prostate cancer. N Engl J Med 2003; 349: 36681.
  • 3
    De Sy WAWP, De Meyer JM, Casselman J, Desmet R, Renders G, Schelfhout W. Long term experience in the treatment of advanced prostatic cancer with decapeptyl, compared to orchiectomy. Acta Urol Belg 1988; 56: 5818.
  • 4
    Stricker HJ. Luteinizing hormone-releasing hormone antagonists in prostate cancer. Urology 2001; 58 (2 Suppl. 1): 247.
  • 5
    Klingmuller D, Schweikert HU. Gonadotropin-releasing hormone: physiological and endocrinological aspects. Recent Results Cancer Res 1992; 124: 16.
  • 6
    Huitema AD, Mathot RA, Tibben MM, Rodenhuis S, Beijnen JH. A mechanism-based pharmacokinetic model for the cytochrome P450 drug–drug interaction between cyclophosphamide and thioTEPA and the autoinduction of cyclophosphamide. J Pharmacokinet Pharmacodyn 2001; 28: 21130.
  • 7
    Weinbauer GF, Nieschlag E. LH-RH antagonists: state of the art and future perspectives. Recent Results Cancer Res 1992; 124: 11336.
  • 8
    Gries JM, Munafo A, Porchet HC, Verotta D. Down-regulation models and modeling of testosterone production induced by recombinant human choriogonadotropin. J Pharmacol Exp Ther 1999; 289: 3717.
  • 9
    Keenan DM, Veldhuis JD. A biomathematical model of time-delayed feedback in the human male hypothalamic–pituitary–Leydig cell axis. Am J Physiol 1998; 275 (1 Part 1): E157E176.
  • 10
    Barton HA, Andersen ME. A model for pharmacokinetics and physiological feedback among hormones of the testicular–pituitary axis in adult male rats: a framework for evaluating effects of endocrine active compounds. Toxicol Sci 1998; 45: 17487.
  • 11
    Heinze K, Keener RW, Midgley AR Jr. A mathematical model of luteinizing hormone release from ovine pituitary cells in perifusion. Am J Physiol 1998; 275 (6 Part 1): E1061E1071.
  • 12
    Liu BZ, Peng JH, Sun YC, Liu YW. A comprehensive dynamical model of pulsatile secretion of the hypothalamo–pituitary–gonadal axis in man. Comput Biol Med 1997; 27: 50713.
  • 13
    Pechstein B, Nagaraja NV, Hermann R, Romeis P, Locher M, Derendorf H. Pharmacokinetic–pharmacodynamic modeling of testosterone and luteinizing hormone suppression by cetrorelix in healthy volunteers. J Clin Pharmacol 2000; 40: 26674.
  • 14
    Nagaraja NV, Pechstein B, Erb K, Klipping C, Hermann R, Locher M, Derendorf H. Pharmacokinetic/pharmacodynamic modeling of luteinizing hormone (LH) suppression and LH surge delay by cetrorelix after single and multiple doses in healthy premenopausal women. J Clin Pharmacol 2003; 43: 24351.
  • 15
    Schwahn M, Nagaraja NV, Derendorf H. Population pharmacokinetic/pharmacodynamic modeling of cetrorelix, a novel LH-RH antagonist, and testosterone in rats and dogs. Pharm Res 2000; 17: 32835.
  • 16
    Fattinger KE, Verotta D, Porchet HC, Munafo A, Le Cotonnec JY, Sheiner LB. Modeling a bivariate control system: LH and testosterone response to the GnRH antagonist antide. Am J Physiol 1996; 271 (4 Part 1): E775E787.
  • 17
    Tornøe CW, Jacobsen JL, Pedersen O, Hansen T, Madsen H. Grey-box modelling of pharmacokinetic/pharmacodynamic systems. J Pharmacokinet Pharmacodyn 2004; 31: 40117.
  • 18
    Kristensen NR, Madsen H, Ingwersen SH. Using stochastic differential equations for PK/PD model development. J Pharmacokinet Pharmacodyn 2005; 32: 10941.
  • 19
    Barron JL, Millar RP, Searle D. Metabolic clearance and plasma half-disappearance time of D-TRP6 and exogenous luteinizing hormone-releasing hormone. J Clin Endocrinol Metab 1982; 54: 116973.
  • 20
    Klippel KF, Winkler CJ, Jocham D, Rubben H, Moser B, Gulati A. [Effectiveness and tolerance of 1 dosage forms (subcutaneous and intramuscular) of decapeptyl depot in patients with advanced prostate carcinoma]. Urologe A 1999; 38: 2705.
  • 21
    Agersø H, Koechling W, Knutsson M, Hjortkjær R, Karlsson MO. The dosing solution influence on the pharmacokinetics of degarelix, a new GnRH antagonist, after s.c. administration to beagle dogs. Eur J Pharm Sci 2003; 20: 33540.
  • 22
    Broqua P, Riviere PJ, Conn PM, Rivier JE, Aubert ML, Junien JL. Pharmacological profile of a new, potent, and long-acting gonadotropin-releasing hormone antagonist: degarelix. J Pharmacol Exp Ther 2002; 301: 95102.
  • 23
    De Pinieux G, Legrier ME, Poirson-Bichat F, Courty Y, Bras-Goncalves R, Dutrillaux AM, Nemati F, Oudard S, Lidereau R, Broqua P, Junien JL, Dutrillaux B, Poupon MF. Clinical and experimental progression of a new model of human prostate cancer and therapeutic approach. Am J Pathol 2001; 159: 75364.
  • 24
    Jiang G, Stalewski J, Galyean R, Dykert J, Schteingart C, Broqua P, Aebi A, Aubert ML, Semple G, Robson P, Akinsanya K, Haigh R, Riviere P, Trojnar J, Junien JL, Rivier JE. GnRH antagonists: a new generation of long acting analogues incorporating p-ureido-phenylalanines at positions 5 and 6. J Med Chem 2001; 44: 45367.
  • 25
    Shah VP, Midha KK, Dighe S, McGilveray IJ, Skelly JP, Yacobi A, Layloff T, Viswanathan CT, Cook CE, McDowall RD. Analytical methods validation: bioavailability, bioequivalence and pharmacokinetic studies. Conference report. Eur J Drug Metab Pharmacokinet 1991; 16: 24955.
  • 26
    Ezan E, Drieu K, Chapelat M, Rougeot C, Dray F. Radioimmunoassay of [D-Trp6]-luteinizing hormone-releasing hormone: its application to animal pharmacokinetic studies after single injection and long-acting formulation administration. Regul Pept 1986; 14: 15567.
  • 27
    Filicori M, Cognigni GE, Arnone R, Pocognoli P, Tabarelli C, Ciampaglia W, Taraborelli S, Casadio P. Subcutaneous administration of a depot gonadotropin-releasing hormone agonist induces profound reproductive axis suppression in women. Fertil Steril 1998; 69: 4439.
  • 28
    Beastall GH, Ferguson KM, O'Reilly DS, Seth J, Sheridan B. Assays for follicle stimulating hormone and luteinising hormone: guidelines for the provision of a clinical biochemistry service. Ann Clin Biochem 1987; 24: 24662.
  • 29
    Clarke SD, Cook J, Imrie G, Noctor TAG. Determination of Suppressed Testosterone Levels in Human Serum by LC-MS/MS. ASMS Annual Meeting 2001, Chicago, USA. Available at http://www.yorkbio.com (last accessed: 27 October 2006).
  • 30
    Imrie GA, Noctor TAG, Lough JA. Method for the Determination of Clinically Suppressed Levels of Testosterone in Human Serum. Bioanalytical Forum 2002, Guildford, UK. Available at http://www.yorkbio.com (last accessed: 27 October 2006).
  • 31
    Beal SL, Sheiner LB. NONMEM User's Guides. San Francisco: NONMEM Project Group, University of California 1994.
  • 32
    Beal SL. Ways to fit a PK model with some data below the quantification limit. J Pharmacokinet Pharmacodyn 2001; 28: 481504.
  • 33
    Tornøe CW, Agersø H, Nielsen HA, Madsen H, Jonsson EN. Population pharmacokinetic modeling of a subcutaneous depot for GnRH antagonist degarelix. Pharm Res 2004; 21: 57484.
  • 34
    Tornøe CW, Overgaard RV, Agersø H, Nielsen HA, Madsen H, Jonsson EN. Stochastic differential equations in NONMEM (R). Implementation, application, and comparison with ordinary differential equations. Pharm Res 2005; 22: 124758.
  • 35
    Parker KL, Schimmer BP. Pituitary hormones and their hypothalamic releasing factors. In: Goodman and Gilman's the Pharmacological Basis of Therapeutics, eds HardmanJG, LimbirdLE, GilmanAG. London: McGraw-Hill 2001: 154163.
  • 36
    Keenan DM, Veldhuis JD. Disruption of the hypothalamic luteinizing hormone pulsing mechanism in aging men. Am J Physiol Regul Integr Comp Physiol 2001; 281: R1917R1924.
  • 37
    Thorner MO, Vance ML, Horvath E, Kovacs K. The anterior pituitary. In: Williams Textbook of Endocrinology, eds WilsonJD, FosterDW. London: W.B. Saunders Co. 1992: 221310.
  • 38
    Singh AB, Norris K, Modi N, Sinha-Hikim I, Shen R, Davidson T, Bhasin S. Pharmacokinetics of a transdermal testosterone system in men with end stage renal disease receiving maintenance hemodialysis and healthy hypogonadal men. J Clin Endocrinol Metab 2001; 86: 243745.
  • 39
    Tornøe CW. Population Pharmacokinetic/Pharmacodynamic Modelling of the Hypothalamic–Pituitary–Gonadal Axis. Informatics and Mathematical Modelling. Kgs Lyngby: Technical University of Denmark 2005.